The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Rasin M.S.

Ukrainskaia meditsinskaia stomatologicheskaia akademiia, Poltava

Peroxisome proliferator-activated receptors-γ and hypertension: Lessons of the history of researches

Authors:

Rasin M.S.

More about the authors

Journal: Therapeutic Archive. 2013;85(9): 118‑123

Read: 3324 times

Download PDF (RU)
Contact the author
Table of contents

PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS-Γ AND HYPERTENSION: LESSONS OF THE HISTORY OF RESEARCHES
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS-Γ AND HYPERTENSION: LESSONS OF THE HISTORY OF RESEARCHES

To cite this article:

Rasin MS. Peroxisome proliferator-activated receptors-γ and hypertension: Lessons of the history of researches. Therapeutic Archive. 2013;85(9):118‑123. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The significance of exogenous nitrate and nitrite of plant origin for vascular health. Russian Journal of Preventive Medi­cine. 2024;(11):141-146
Predictors of Enga­gement and Active participation of Patients with Unco­ntrolled Hype­rtension in the Tele­health Surveillance Program. Russian Journal of Preventive Medi­cine. 2024;(12):37-43
Effi­cacy and tole­rability of azilsartan combined with amlo­dipine and amlo­dipine mono­therapy and combinations of amlo­dipine with other angiotensin II rece­ptor blockers. Russian Cardiology Bulletin. 2024;(4-2):161-171
Risk factors and adve­rse outcomes of cardiovascular diseases in people with high normal blood pressure of the Ryazan region. (5-year prospective follow-up). Russian Journal of Preventive Medi­cine. 2025;(2):31-37
Diagnostics of hype­rtensive diso­rders in cardio-obstetrics: current state-of-affairs. Russian Journal of Human Reproduction. 2025;(1):63-77
Study of the levo­carnitine effi­cacy for the treatment of mode­rate cognitive impairment in patients with hype­rtension. Russian Journal of Preventive Medi­cine. 2025;(4):45-50
Visceral obesity is a reve­rsible factor in pathogenesis of major cardiovascular diseases. Russian Cardiology Bulletin. 2025;(3):11-16
Features of the inte­rpretation of bodily sensations by patients with arte­rial hype­rtension. Russian Journal of Preventive Medi­cine. 2025;(10):82-87
Study of the effe­ctiveness of the drug Elca­rnitine in the correction of increased variability of arte­rial pressure in patients with hype­rtensive disease and cognitive dysfunction. Russian Journal of Preventive Medi­cine. 2025;(10):88-92
Abstract:

The paper analyzes data from the clinical use of thiazolidinediones, human genetic observations and experiments with peroxisome proliferator-activated receptor (PPAR-α) gene removal, and also those on the role of PPAR-γ and -Β in the function of the vascular endothelium, sympathetic autonomic nervous system, and renal sodium reabsorption. It is concluded that the tonic activity of PPAR is a universal protective mechanism counteracting the development of hypertension.

Keywords:

peroxisome proliferator-activated receptors-γ
hypertension
thiazolidinediones.

Authors:

Rasin M.S.

Ukrainskaia meditsinskaia stomatologicheskaia akademiia, Poltava

Close metadata

References:

  1. Issemann I., Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Proc Natl Acad Sci USA 1999; 47: 645-650.
  2. Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-688.
  3. Lehmann J.M., Moore L.B., Smith-Oliver T.A. et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-12956.
  4. Getz G.S. Bridging the innate and adaptive immune systems. J Lipid Res 2005; 46: 619-627.
  5. Barroso I., Gurnell M., Crowley V.E.F. et al. Dominant negative mutations in human PPAR are associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402: 880-883.
  6. Pascual G., Fong A. L., Ogawa S. et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Proc Natl Acad Sci USA 2005; 402: 880-883.
  7. Gurnell M., David B., Savage E. et al. PPAR ligand resistance (PLR) syndrome. The Metabolic Syndrome: Peroxisome Proliferator-Activated Receptor and Its Therapeutic Modulation. J Clin Endocrinol Metab 2003; 88: 2412-2421.
  8. Fonseca V.A. Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease. Am J Cardiol 2003; 18: 50J-60J.
  9. Reaven G.M. Relationships Among Insulin Resistance, Type 2 Diabetes, Essential Hypertension, and Cardiovascular Disease: Similarities and Differences. J Clin Hypertens 2011; 13: 238-243.
  10. Rasin A.M., Kaidashev I.P., Rasin M.S. Peroksisom proliferatoraktiviruyushchie retseptory i ikh rol' v sistemnom vospalenii, aterogeneze, arterial'noi gipertenzii i khronicheskom obstruktivnom zabolevanii legkikh (obzor literatury). Ukraїns'kii ter zhurn 2006; 2: 100-108.
  11. Desvergne V., Michalik L., Wahli W. Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol Endocrinol 2004; 18 (6): 1321-1332.
  12. Grundy S.M. Inflammation, hypertension, and the metabolic syndrome. JAMA 2003; 290: 3000-3002.
  13. Agostini M., Gurnell M., Savage D.B. et al. Tyrosine Agonists Reverse the Molecular Defects Associated with Dominant-Negative Mutations in Human Peroxisome Proliferator-Activated Receptor. Endocrinology 2004; 145: 1527-1538.
  14. Agarwal A.K., Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy J Clin Endocrinol Metab 2002; 87: 408-411.
  15. Kaidashev I.P. NF-κB-signalizatsiya kak osnova razvitiya sistemnogo vospaleniya, insulinorezistentnosti, lipotoksichnosti, sakharnogo diabeta 2-go tipa i ateroskleroza. Mezhdunar endokrinol zhurn 2011; 3 (35): 35-40.
  16. Kaidashev І.P., Rasіn O.M., Mikityuk M.V., Rasіn M.S. Atorvastatin ta roziglіtazon іndukuyut' apoptoz monotsitіv/makrofagіv krovі: rol' polіmorfіzmu gena PPARγ. Lіki 2007; 3-4: 55-61.
  17. Stefanski A., Majkowska1L., Ciechanowicz A. et al. Association between the Pro12Ala variant of the peroxisome proliferator-activated receptor-gamma2 gene and increased 24-h diastolic blood pressure in obeshe patients with type II diabetes. J Hum Hypertens 2006; 20; 684-692.
  18. Potenza M.A., Gagliardi S., De Benedictis A. et al. Endocrinol Metab 2009; 297: E685-E694.
  19. Tsai Y.S., Kim H.J., Takahashi N. et al. J Clin Invest 2009; 114: 240-249.
  20. Beyer A.M. Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling. Hypertension 2008; 51: 867-871.
  21. Kleinhenz J.M., Kleinhenz D.J., You S. et al. Am J Physiol Heart Circ Physiol 2009; 297: H1647-H1654.
  22. Chang L., Villacorta L., Zhanget J. et al. Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-gamma deletion leads to hypotension. Circulation 2009; 119: 2161-2169.
  23. Reaven G.M., Lithell H., Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-381.
  24. Stuhlinger M.C., Abbasi F., Chu J.W. et al. Relationship between insulin resistance and an endogenous nitiric oxide synthase inhibitor. JAMA 2002; 287: 1420-1426.
  25. Liu Z. The renin-angiotensin system and insulin resistance. Curr Diab Rep 2007; 7 (1): 34-42.
  26. Memisoglu A., Hu F.B., Hankinson S.E. et al. http://www.ncbi.nlm.nih.gov/pubmed?term=Manson%20JE%5BAuthor%5D&cauthor=true&cauthor_uid=14506127. Interaction between a peroxisome proliferator-activated receptor gamma gene polymorphism and dietary fat intake in relation to body mass. Hum Mol Genet 2003; 12: 2923-2929.
  27. Huang C.L., Kuo E. Mechanisms of Disease: WNK-ing at the mechanism of salt-sensitive hypertension. Nature Clin Pract Nephrol 2007; 3 (11): 623-630.
  28. Reaven G.M., Hoffman B.B. A role for insulin in the aetiology and course of hypertension? Lancet 1987; 2 (8556): 435-437.
  29. Steinberg H.O., Brechtel G., Johnson A. et al. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Investigat 1994; 94 (3): 1172-1179.
  30. Robitaille J., Despres J.P., Perusse L., Vohl M.C. The PPAR-gamma P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the Quebec Family Study. Clin Genet 2003; 63: 109-116.
  31. Schlaich M.P., Lambert E., Kaye D.M. et al. Sympathetic nervous augmentation in essential hypertension: role of nerve firing, norepinephrine reuptake and angiotensin neuromodulation. Hypertension 2004; 43: 169-175.
  32. Esler M.D., Krum H., Sobotka P.A. et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial. Lancet 2010; 376: 1903-1909.
  33. Festa A., D'Agostino Jr R., Howard G. et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47.
  34. Aizawa-Abe M., Ogawa Y., Masuzaki H. et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2010; 105: 1243-1252.
  35. Bataineh A., Raij L. Angiotensin II, nitric oxide, and end-organ damage in hypertension. Kidney Int Suppl 1998; 68: S14-S19.
  36. Sesso H.D., Buring J.E., Rifai N. et al. C-reactive protein and the risk of developing ypertension. JAMA 2003; 290: 2945-2951.
  37. Li J., Doerffel Y., Hocher C.B. Inflammation in the genesis of hypertension and its complications-the role of angiotensin II. Nephrol Dialys Transplantat 2007; 22 (11): 3107-3109.
  38. Christopher B.J., Gregory Y.H. Is Hypertension an Inflammatory Process? Cur Pharmaceut Design 2006; 12: 1623-1635.
  39. Cheng Z.J., Vapaatalo H., Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 2005; 11: RA194-RA205.
  40. Pauletto P., Rattazzi M. Inflammation and hypertension: the search for a link. Nephrol Dial Transplant 2006; 21: 850-853.
  41. Endemann D.H., Schiffrin E.L. Endothelial Dysfunction. J Am Soc Nephrol 2004; 15: 1983-1992.
  42. Licastro F., Candore G., Domenico Lio et al. Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun Ageing 2005; 2: 8-17.
  43. Lonn E.M., Gerstein H.C., Sheridan P. et al. Diabetes reduction assessment with ramipril and rosiglitazone medication. J Am Coll Cardiol 2009; 53: 2028-2035.
  44. Ricote M., Valledor A.F., Glass C.K. Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 230-239.
  45. Clarke D.L., Patel H.J., Mitchell .A. Regulation of the release of colony-stimulating factors from human airway smooth muscle cells by prostaglandin E2. Br J Pharmacol 2001; 133: 40-45.
  46. Al-Shali K.Z., House A.A., Hanley J.G. et al. Genetic Variation in PPARG Encoding Peroxisome Proliferator-Activated Receptor {gamma} Associated With Carotid Atherosclerosis. Stroke 2004; 35 (9): 2036-2040.
  47. Nie M., Corbett L., Knox A.J., Pang L. Differential regulation of chemokine expression by peroxisome proliferator-activated receptor gamma agonists: Interactions with glucocorticoids and beta 2-agonists. Biol Chem 2004; 324: 47-50.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.